BIOAUXILIUM-RESEARCH-INC
19.2.2020 15:46:13 CET | Business Wire | Press release
Bioauxilium Research Inc. , a Canadian biotech specialized in the development and manufacturing of world-class time-resolved Förster resonance energy transfer (TR‑FRET) assay kits, announced today the launch of its proprietary no-wash THUNDER™ TR‑FRET cellular platform with the introduction of 68 new cell signaling assay kits. These top-quality, fully validated yet affordable cell-based kinase kits were designed to enable the simple, rapid and sensitive semi-quantitative detection of specific intracellular phosphorylated and/or total proteins in cell lysates.
The ready-to-use THUNDER™ Cell Signaling Assay Kits are based on the higher specificity sandwich immunoassay format. However, in contrast to both conventional and improved ELISAs, they use a no-wash protocol with only one reagent addition and incubation step. This streamlined protocol dramatically decreases hands-on time and assay variability and is easily amenable to automation for high-throughput screening (HTS). The assays can be run in the same low volume using either half-area 96-well or low-volume 384-well plates.
The THUNDER™ assay kits combine rigorously validated antibodies, the best compatible FRET fluorophores and stringent manufacturing standards to ensure specificity, enhanced TR‑FRET assay performance and lot-to-lot consistency. All kits are subjected to a rigorous validation process using lysates from cells treated with pathway-specific activators and inhibitors, to further confirm target specificity and demonstrate performance under real assay conditions. Validation data are included in the accompanying datasheets, the most comprehensive on the market. All kits are available in several kit sizes suitable for both lab-scale experiments and high-throughput screens.
“THUNDER™ is an affordable cell-based assay platform that provides easy access to the powerful TR‑FRET technology for all researchers looking to quantify low amounts of endogenous proteins in cells,” said Jaime Padros, Ph.D., President, Bioauxilium. “We believe THUNDER™ provides for the first time a real, cost-effective alternative to ELISAs and other proprietary TR‑FRET as well as bead-based assay technologies.”
THUNDER™ kits are available worldwide and can be purchased directly through the Bioauxilium website or through one of Bioauxilium’s authorized distributors.
The THUNDER™ TR‑FRET technology is also available on request to Bioauxilium’s customers for custom antibody labelling and assay development services.
For more information on Bioauxilium and THUNDER™, visit www.bioauxilium.com .
About Bioauxilium Research Inc.
Bioauxilium is a private Canadian biotechnology company founded by expert industry scientists. It focuses on the design, development and manufacturing of top-quality, fully-validated assay kits that simplify laboratory workflow and accelerate biomedical research. Since its inception in 2013, Bioauxilium has licensed hundreds of TR‑FRET assay kits enabling the quantification of cellular proteins and biomarkers. Bioauxilium’s kits are based on its proprietary THUNDER™ TR-FRET technology. They are offered at an outstanding value and are supported by expert technical support. Bioauxilium also provides on a contract basis customized services in assay development using diverse technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005603/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Executive Leadership Appointments25.3.2026 14:00:00 CET | Press release
Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat
Andersen Consulting indgår en samarbejdsaftale med Ventum Consulting25.3.2026 13:58:00 CET | Pressemeddelelse
Andersen Consulting udvider sin globale platform med tilføjelsen af samarbejdspartneren Ventum Consulting, der er et forretnings- og teknologikonsulenthus med base i Tyskland, der specialiserer sig i digital transformation, enterprise agility, produktudvikling, datadrevet innovation samt nye teknologier såsom AI. Ventum Consulting hjælper organisationer med at bygge bro mellem forretning og teknologi ved at levere skræddersyede løsninger inden for strategi, procesoptimering og implementering af it-løsninger. Virksomhedens ekspertise omfatter data og AI, cybersikkerhed, enterprise architecture, bæredygtighed, cloud-transformation samt agile enablement, hvilket kun er et udsnit af deres omfattende serviceportefølje. Ventum Consulting arbejder med kunder på tværs af brancher, herunder bilindustri og produktion, finansielle tjenester og forsikring, sundhedssektoren og life science-industrien samt den offentlige sektor, for at accelerere digital transformation, styrke driftsmæssig robusthed
OCP Announces Date of Fourth Quarter and Full Year 2025 Earnings25.3.2026 13:30:00 CET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2025 results on Wednesday, April 1, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts, and market makers on the OCP Intralinks portal from 9:00 a.m. EST, 2:00 p.m. Morocco and London time (GMT+1). OCP senior management will host a conference call to discuss fourth quarter and full year 2025 results at 10:00 a.m. EST, 3:00 p.m. Morocco andLondon time (GMT+1),on Wednesday, April 1, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts, and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive
SLB Industrializes AI for the Energy Industry with NVIDIA25.3.2026 13:00:00 CET | Press release
Companies will develop modular data center infrastructure and generative AI models for large-scale deployments Global energy technology company SLB (NYSE: SLB) today announced an expansion of its technology collaboration with NVIDIA to design and deploy critical AI infrastructure and models for the energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324731936/en/ SLB’s technology center in Louisiana: a 3.1 million square-foot facility dedicated to manufacturing for its modular data center business. The work focuses on three strategic elements: Modular design for data centers: SLB will serve as the modular design partner for NVIDIA DSX AI factories. This modular approach, where components are manufactured offsite, will drive increased quality and reliability while also reducing costs, labor constraints and lead times. It also enables rapid and flexible scaling, which allows customers to expand data center capac
Pokémon Trading Card Game has premiered at the Tokyo Metropolitan Government Building!25.3.2026 11:00:00 CET | Press release
Nashiko Momotsuki, Gorgeous, Tosa Brothers, and Pikachu led the countdown with 5,000 visitors In its efforts to promote nighttime tourism, the Tokyo Metropolitan Government is developing new attractions that illuminate the capital after dark. As part of this initiative, projection mapping is being presented year-round on the iconic Tokyo Metropolitan Government Building No. 1, transforming its façade into a canvas of light and sound. We are pleased to announce the launch of a new projection mapping show inspired by the globally beloved Pokémon Trading Card Game, which celebrates its 30th anniversary this year. “Pokémon Trading Card Game: TOKYO LUMINOUS NIGHT” has been launched on Friday, March 20 (national holiday). On opening day, a special event was held featuring Nashiko Momotsuki, Gorgeous, Tosa Brothers, and Pikachu as special guests. Together with the 5,000 visitors gathered at the venue, they led the countdown to the first screening. This press release features multimedia. View
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom